No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
A Monte Carlo model for out-of-field dose calculation from high-energy photon therapy
1.K. R. Kase, G. K. Svensson, A. B. Wolbarst, and M. A. Marks, “Measurements of dose from secondary radiation outside a treatment field,” Int. J. Radiat. Oncol. Biol. Phys. 9, 1177–1183 (1983).
2.R. Nath, A. Boyer, P. D. LaRiviere, R. C. McCall, and K. W. Price, AAPM Report No. 19: Neutron Measurements Around High Energy X-Ray Radiotherapy Machines. A Report of Task Group 27, Radiation Therapy Committee, American Association of Physicists in Medicine (AAPM, New York, 1986).
3.National Council on Radiation Protection and Measurements, Neutron Contamination from Medical Electron Accelerators, NCRP Report 79 (National Council on Radiation Protection and Measurements, Bethesda, Maryland, 1984).
4.National Council on Radiation Protection and Measurements, The Relative Biological Effectiveness of Rradiations of Different Quality, NCRP Report 104 (National Council on Radiation Protection and Measurements, Bethesda, Maryland, 1990).
5.E. J. Hall, S. G. Martin, H. Amols, and T. K. Hei, “Photoneutrons from medical linear accelerators: Radiobiological measurements and risk estimates,” Int. J. Radiat. Oncol. Biol. Phys. 33, 225–230 (1995).
6.S. F. Kry, M. Salehpour, D. Followill, M. Stovall, D. Kuban, R. White, and I. Rosen, “The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy,” Int. J. Radiat. Oncol. Biol. Phys. 62, 1195–1203 (2005).
7.R. M. Howell, N. E. Hertel, Z. Wang, J. Hutchinson, and G. D. Fullerton, “Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV, and 18 MV beam energies,” Med. Phys. 33, 360–368 (2006).
8.D. J. Brenner, R. E. Curtis, E. J. Hall, and E. Ron, “Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery,” Cancer 88, 398–406 (2000).
9.J. D. Boice, Jr. et al., “Second cancers following radiation treatment for cervical cancer: An international collaboration among cancer registries,” J. Natl. Cancer Inst. 74, 955–975 (1985).
11.C. Rubino, E. Adjadj, S. Guerin, C. Guibout, A. Shamsaldin, M. G. Dondon, D. Valteau-Couanet, O. Hartmann, M. Hawkins, and F. de Vathaire, “Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment,” Int. J. Cancer 107, 791–796 (2003).
12.C. Rubino, F. de Vathaire, M. E. Dottorini, P. Hall, C. Schvartz, J. E. Couette, M. G. Dondon, M. T. Abbas, C. Langlois, and M. Schlumberger, “Second primary malignancies in thyroid cancer patients,” Br. J. Cancer 89, 1638–1644 (2003).
13.H. M. Lin and M. A. Teitell, “Second malignancy after treatment of pediatric hodgkin disease,” J. Pediatr. Hematol. Oncol. 27, 28–36 (2005).
14.S. Bhatia, Y. Yasui, L. L. Robison, J. M. Birch, M. K. Bogue, L. Diller, C. DeLaat, F. Fossati-Bellani, E. Morgan, O. Oberlin, G. Reaman, F. B. Ruymann, J. Tersak, and A. T. Meadows, “High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: Report from the late effects study group,” J. Clin. Oncol. 21, 4386–4394 (2003).
15.D. L. Preston, Y. Shimizu, D. A. Pierce, A. Suyama, and K. Mabuchi, “Studies of mortality of atomic bomb survivors, Report 13: Solid cancer and noncancer disease mortality: 1950-1997,” Radiat. Res. 160, 381–407 (2003).
16.G. Wilde and J. Sjöstrand, “A clinical study of radiation cataract formation in adult life following gamma irradiation of the lens in early childhood,” Br. J. Ophthalmol. 81, 261–266 (1997).
17.D. Followill, P. Geis, and A. Boyer, “Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy,” Int. J. Radiat. Oncol. Biol. Phys. 38, 667–672 (1997).
18.S. Mutic and D. A. Low, “Whole-body dose from tomotherapy delivery,” Int. J. Radiat. Oncol. Biol. Phys. 42, 229–232 (1998).
19.D. Verellen and F. Vanhavere, “Risk assessment of radiation-induced malignancies based on whole-body dose equivalent estimates for IMRT in the head and neck region,” Radiother. Oncol. 53, 199–203 (1999).
20.S. F. Kry, M. Salehpour, D. Followill, M. Stovall, D. Kuban, R. A. White, and I. Rosen, “Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy,” Int. J. Radiat. Oncol. Biol. Phys. 62, 1204–1216 (2005).
21.R. M. Howell, M. S. Ferenci, N. E. Hertel, and G. Fullerton, “Investigation of secondary neutron dose for 18 MV dynamic MLC IMRT delivery,” Med. Phys. 32, 786–793 (2005).
22.M. Stovall, C. R. Blackwell, J. Cundiff, D. H. Novack, J. R. Palta, L. K. Wagner, E. W. Webster, and R. J. Shalek, “Fetal dose from radiotherapy with photon beams: Report of AAPM Radiation Therapy Committee Task Group No. 36,” Med. Phys. 22, 63–82 (1995).
23.S. F. Kry, U. Titt, F. Pönisch, D. Followill, O. N. Vassiliev, R. A. White, R. Mohan, and M. Salehpour, “A Monte Carlo model for calculating out-of-field dose from a Varian 6-MV beam,” Med. Phys. 33, 4405–4413 (2006).
24.National Council on Radiation Protection and Measurements, Limitation of Exposure to Ionizing Radiation, NCRP Report 116 (National Council on Radiation Protection and Measurements, Bethesda, Maryland, 1993).
25.ICRP, ICRP Publication 60: 1990 Recommendations of the International Commission on Radiological Protection, 1990.
26.X. S. Mao, K. R. Kase, J. C. Liu, W. R. Nelson, J. H. Kleck, and S. Johnsen, “Neutron sources in the Varian Clinac 2100C/2300C medical accelerator calculated by the EGS4 code,” Health Phys. 72, 524–529 (1997).
27.K. R. Kase, X. S. Mao, W. R. Nelson, J. C. Liu, J. H. Kleck, and M. Elsalim, “Neutron fluence and energy spectra around the Varian Clinac 2100C/2300C medical accelerator,” Health Phys. 74, 38–47 (1998).
28.R. Barquero, T. M. Edwards, M. P. Iniguez, and H. R. Vega-Carrillo, “Monte Carlo simulation estimates of neutron doses to critical organs of a patient undergoing 18 MV x-ray LINAC-based radiotherapy,” Med. Phys. 32, 3579–3588 (2005).
29.J. Lehmann, R. Stern, T. Daly, D. Rocke, C. Schwietert, G. Jones, M. Arnold, C. Siantar, and Z. Goldberg, “Dosimetry for quantitative analysis of the effects of low-dose ionizing radiation in radiation therapy patients,” Radiat. Res. 165, 240–247 (2006).
30.J. S. Hendricks et al., MCNPX, Version 2.5. e, LA-UR-04–0569, 2004.
31.F. Pönisch, U. Titt, S. F. Kry, O. N. Vassiliev, and R. Mohan, “MCNPX simulation of a multileaf collimator,” Med. Phys. 33, 402–404 (2006).
32.P. Keall, J. Siebers, B. Libby, and R. Mohan, “Determining the incident electron fluence for Monte Carlo-based photon treatment planning using a standard measured data set,” Med. Phys. 30, 574–582 (2003).
33.C. L. Hartmann Siantar, R. S. Walling, T. P. Daly, B. Faddegon, N. Albright, P. Bergstrom, A. F. Bielajew, C. Chuang, D. Garrett, R. K. House, D. Knapp, D. J. Wieczorek, and L. J. Verhey, “Description and dosimetric verification of the PEREGRINE Monte Carlo dose calculation system for photon beams incident on a water phantom,” Med. Phys. 28, 1322–1337 (2001).
34.D. Sheikh-Bagheri and D. W. O. Rogers, “Sensitivity of megavoltage photon beam Monte Carlo simulations to electron beam and other parameters,” Med. Phys. 29, 379–390 (2002).
35.G. X. Ding, “Energy spectra, angular spread, fluence profiles and dose distributions of 6 and 18 MV photon beams: Results of Monte Carlo simulations for a Varian 2100EX accelerator,” Phys. Med. Biol. 47, 1025–1046 (2002).
36.S. McCormack, J. Diffey, and A. Morgan, “The effect of gantry angle on megavoltage photon beam attenuation by a carbon fiber couch insert,” Med. Phys. 32, 483–487 (2005).
37.B. R. L. Siebert and H. Schumacher, “Quality factors, ambient, and personal dose equivalent for neutrons, based on the new ICRU stopping power data for protons and alpha particles,” Radiat. Prot. Dosimetry 58, 177–183 (1995).
38.H. Schumacher and B. R. L. Siebert, “Quality factors and ambient dose equivalent for neutrons based on the new ICRP recommendations,” Radiat. Prot. Dosimetry 40, 85–89 (1992).
39.C. P. J. Raaijmakers, M. W. Konijnenberg, H. W. Verhagen, and B. J. Mijnheer, “Determination of dose components in phantoms irradiated with an epithermal neutron beam for boron neutron capture therapy,” Med. Phys. 22, 321–329 (1995).
40.H. M. Liu, P. C. Hsu, and T. F. Liaw, “Gamma dose measurement in a water phantom irradiation with the BNCT facility at THOR,” Radiat. Prot. Dosimetry 95, 353–358 (2001).
41.R. Méndez, M. P. Iñiguez, R. Barquero, A. Mañanes, E. Gallego, A. Lorente, and M. Voytchev, “Response components of LiF:Mg, Ti around a moderated Am-Be meutron source,” Radiat. Prot. Dosimetry 98, 173–178 (2002).
42.T. H. Kirby, W. F. Hanson, and D. A. Johnston, “Uncertainty analysis of absorbed dose calculations from thermoluminescence dosimeters,” Med. Phys. 19, 1427–1433 (1992).
43.S. D. Davis, C. K. Ross, P. N. Mobit, L. Van der Zwan, W. J. Chase, and K. R. Shortt, “The response of LiF thermoluminescence dosemeters to photon beams in the energy range from 30 kV X-rays to 60Co gamma rays,” Radiat. Prot. Dosimetry 106, 33–43 (2003).
44.D. Sheikh-Bagheri and D. W. O. Rogers, “Monte Carlo calculation of nine megavoltage photon beam spectra using the BEAM code,” Med. Phys. 29, 391–402 (2002).
46.S. Mutic and E. E. Klein, “A reduction in the AAPM TG-36 reported peripheral dose distributions with tertiary multileaf collimation, American Association of Physicists in Medicine Task Group 36,” Int. J. Radiat. Oncol. Biol. Phys. 44, 947–953 (1999).
48.D. Followill, M. Stovall, S. F. Kry, and G. Ibbott, “Neutron source strength measurements for Varian, Siemens, Elekta, and General Electric linear accelerators,” J. Appl. Clin. Med. Phys. 4, 189–194 (2003).
Article metrics loading...
Full text loading...
Most read this month